切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (05) : 251 -256. doi: 10.3877/cma.j.issn.2095-3216.2015.05.007

所属专题: 文献

综述

糖尿病肾病治疗的循证医学新进展
韩雅纯1, 孙林1,()   
  1. 1. 410011 长沙,中南大学肾脏病研究所、湖南省血液净化与肾脏病重点实验室、湘雅二医院肾内科
  • 出版日期:2015-10-28
  • 通信作者: 孙林
  • 基金资助:
    国家自然科学基金(81270812, 81370832,81470960)

New advancements of evidenced-based medical treatment of diabetic nephropathy

Yachun Han1, Lin Sun1,()   

  1. 1. Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
  • Published:2015-10-28
  • Corresponding author: Lin Sun
  • About author:
    Corresponding author: Sun Lin, Email:
引用本文:

韩雅纯, 孙林. 糖尿病肾病治疗的循证医学新进展[J]. 中华肾病研究电子杂志, 2015, 04(05): 251-256.

Yachun Han, Lin Sun. New advancements of evidenced-based medical treatment of diabetic nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(05): 251-256.

随着糖尿病(DM)发病率的逐年上升,糖尿病肾病(DN)已成为引起我国乃至全球终末期肾病的一个主要原因,因此其治疗问题也成为临床肾脏病学界的一个重要焦点。近年来,DN治疗的循证医学研究取得了一些新的进展,如合理地控制血糖、血压,调节血脂,降低蛋白尿,保护肾功能等治疗措施的更新,在一定程度上改变了人们以往对DN治疗的认识。对防治DN并发症,延缓DN进展,降低患者心血管疾病及死亡发生率具有重要的临床价值。该文结合文献资料及我们以往的工作对DN治疗循证医学新进展予以综述。

With the increasing incidence of diabetes mellitus (DM) year by year, diabetic nephropathy (DN) has become one of the major causes of end-stage renal disease in the world. Therefore, its medical treatment has become the focus of attention. Recently, new advancements in evidence-based treatment of DN have been shown in reasonably controlling hyperglycemia, hypertension, dyslipidemia, reducing proteinuria, and protecting renal function. These measures have updated the previous recognition of treatments, and have significant clinical value in prevention and treatment of complications, slowing down the progression of DN, and reducing the incidence of cardiovascular diseases and death. Here we reviewed the new advancements of evidenced-based treatment of diabetic nephropathy according to the related publications.

1
Breyer MD, Coffman TM, Flessner MF, et al. Diabetic nephropathy: a national dialogue [J]. Clin J Am Soc Nephrol, 2013, 8 (9): 1603-1605.
2
Liu ZH. Nephrology in China [J]. Nat Rev Nephrol, 2013, 9 (9): 523-528.
3
Sandbaek A, Griffin SJ, Sharp SJ, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study [J]. Diabetes Care, 2014, 37 (7): 2015-2023.
4
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J]. BMJ, 2000, 321 (7258): 405-412.
5
Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis [J]. PLoS One, 2012, 7 (8): e42551.
6
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993, 329 (14): 977-986.
7
de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes [J]. N Engl J Med, 2011, 365 (25): 2366-2376.
8
Udell JA, Cavender MA, Bhatt DL, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials [J]. Lancet Diabetes Endocrinol, 2015, 3 (5): 356-366.
9
Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes [J]. N Engl J Med, 2014, 371 (21): 1972-1982.
10
Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes [J]. N Engl J Med, 2011, 364 (9): 818-828.
11
Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial [J]. Diabetes Care, 2014, 37 (3): 634-643.
12
Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18, 168 people with type 1 diabetes: observational study [J]. BMJ, 2015, 350: h3234.
13
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations [J]. Ann Intern Med, 2011, 154 (9): 602-613.
14
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. N Engl J Med, 2013, 369 (14): 1317-1326.
15
Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus [J]. Ther Adv Endocrinol Metab, 2015, 6 (1): 3-18.
16
Hong J, Zhang Y, Lai S, et al. Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care, 2013, 36: 1304-1311 [J]. Diabetes Care, 2014, 37 (1): e21.
17
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. Lancet, 2009, 373 (9681): 2125-2135.
18
Glassock RJ, Bakris GL. Hypertension: Impact of blood pressure lowering in type 2 diabetes [J]. Nat Rev Nephrol, 2015, 11 (6): 320-321.
19
KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease [J]. Am J Kidney Dis, 2007, 49 (2 Suppl 2): S12-S154.
20
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus [J]. N Engl J Med, 2010, 362 (17): 1575-1585.
21
Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis [J]. JAMA, 2015, 313 (6): 603-615.
22
Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Kidney Inter Suppl, 2012, 2(5): 337-414.
23
Roberts MA. Commentary on the KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Nephrology (Carlton), 2014, 19 (1): 53-55.
24
Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) [J]. Nephrol Dial Transplant, 2015, 30(Suppl 2): ii1-142.
25
Luo Y, Yang SK, Zhou X, et al. Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis [J]. Ren Fail, 2015, 37 (4): 614-634.
26
Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis [J]. Lancet, 2015, 385 (9982): 2047-2056.
27
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy [J]. N Engl J Med, 2013, 369 (20): 1892-1903.
28
Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies [J]. BMC Cardiovasc Disord, 2014, 14: 148.
29
Yamamoto S, Okada Y, Mori H, et al. Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide [J]. Intern Med, 2014, 53 (12): 1283-1289.
30
Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes [J]. N Engl J Med, 2014, 371 (15): 1392-1406.
31
Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial [J]. Diabetes Care, 2013, 36 (9): 2508-2515.
32
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis [J]. Ann Intern Med, 2013, 159 (4): 262-274.
33
Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis [J]. BMJ Open, 2013, 3(1): pii: e001986.
34
Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study [J]. Lancet Diabetes Endocrinol, 2014, 2 (11): 894-900.
35
Tonelli M, Wanner C. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline [J]. Ann Intern Med, 2014, 160 (3): 182.
36
Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) [J]. Am J Kidney Dis, 2009, 54 (5): 810-819.
37
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J]. Lancet, 2011, 377 (9784): 2181-2192.
38
Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis [J]. Eur Heart J, 2013, 34 (24): 1807-1817.
39
Krane V, Winkler K, Drechsler C, et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus [J]. Am J Kidney Dis, 2009, 54 (5): 902-911.
40
Marz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis [J]. Clin J Am Soc Nephrol, 2011, 6 (6): 1316-1325.
41
Margolis KL, O′Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial [J]. Diabetes Care, 2014, 37 (6): 1721-1728.
42
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol, 2014, 63 (25 Pt B): 2889-2934.
43
American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers [J]. Clin Diabetes, 2015, 33 (2): 97-111.
44
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [J]. JAMA, 2008, 300 (18): 2134-2141.
45
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease [J]. BMJ, 2008, 337: a1840.
46
Ekstrom N, Cederholm J, Zethelius B, et al. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register [J]. BMJ Open, 2013, 3(4) pii: e002688.
47
Sasso FC, Marfella R, Pagano A, et al. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study [J]. Acta Diabetol, 2015, 52 (2): 239-247.
48
de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial [J]. Lancet, 2010, 376 (9752): 1543-1551.
49
Krairittichai U, Mahannopkul R, Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease[J]. J Med Assoc Thai, 2012, 95(Suppl 3): S41-S47.
50
de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review [J]. J Am Soc Nephrol, 2013, 24 (11): 1863-1871.
51
Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial [J]. JAMA, 2012, 307 (7): 674-684.
52
Shan D, Wu HM, Yuan QY, et al. Pentoxifylline for diabetic kidney disease [J]. Cochrane Database Syst Rev, 2012, 2: CD006800.
53
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial [J]. J Am Soc Nephrol, 2015, 26 (1): 220-229.
54
Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes [J]. N Engl J Med, 2011, 365 (4): 327-336.
55
de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease [J]. N Engl J Med, 2013, 369 (26): 2492-2503.
[1] 中华医学会骨科学分会关节外科学组, 广东省医学会骨质疏松和骨矿盐疾病分会, 广东省佛山市顺德区第三人民医院. 中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(06): 751-764.
[2] 许正文, 李振, 侯振扬, 苏长征, 朱彪. 富血小板血浆联合植骨治疗早期非创伤性股骨头坏死[J]. 中华关节外科杂志(电子版), 2023, 17(06): 773-779.
[3] 李培杰, 乔永杰, 张浩强, 曾健康, 谭飞, 李嘉欢, 王静, 周胜虎. 细菌培养阴性的假体周围感染诊治的最新进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 827-833.
[4] 王宏宇. 固定与活动平台假体在全膝关节置换术中的应用价值[J]. 中华关节外科杂志(电子版), 2023, 17(06): 871-876.
[5] 李善武, 叶永杰, 王兵, 王子呓, 银毅, 孙官军, 张大刚. 胫骨高位截骨与单髁置换的早期疗效比较[J]. 中华关节外科杂志(电子版), 2023, 17(06): 882-888.
[6] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[7] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[8] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[9] 邱朋, 邓正栋, 王剑明. 肝内胆管结石微创治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 591-596.
[10] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[11] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[12] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[13] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要